[HTML][HTML] IL-1 Inhibitors in the Treatment of Familial Mediterranean Fever: Treatment Indications and Clinical Features in a Large Real-World Cohort

M Yalcin-Mutlu, OC Icacan, F Yildirim… - Journal of Clinical …, 2024 - mdpi.com
Background: The accruing evidence about the efficacy of anti-IL-1 agents in Familial
Mediterranean Fever (FMF) patients led to their widespread off-label use. Therefore …

[HTML][HTML] The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review

V Hentgen, C Vinit, A Fayand… - Frontiers in …, 2020 - frontiersin.org
Purpose: Familial Mediterranean fever (FMF) is the most common monogenic auto-
inflammatory disease characterized by recurrent attacks of fever and serositis. It is …

[HTML][HTML] Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management

S Özen, ED Batu, S Demir - Frontiers in immunology, 2017 - frontiersin.org
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory
disease (AID) affecting mainly the ethnic groups originating from Mediterranean basin. The …

Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review

A Tufan, H LACHMANN - Turkish Journal of Medical …, 2020 - journals.tubitak.gov.tr
Abstract Familial Mediterranean fever (FMF)(OMIM# 249100) is the most common hereditary
autoinflammatory disease in the world. FMF is caused by gain of function mutations of MEFV …

Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis

B Kilic, Y Guler, FN Azman, E Bostanci… - Rheumatology, 2024 - academic.oup.com
Objectives FMF is the most common hereditary monogenic fever syndrome marked by
recurrent attacks of fever and polyserositis. Colchicine is the current recommended first-line …

Current therapeutic options for managing familial Mediterranean fever

ED Batu, ZS Arici, Y Bilginer, S Özen - Expert Opinion on Orphan …, 2015 - Taylor & Francis
Introduction: Familial Mediterranean fever (FMF) is a monogenic auto-inflammatory disease
characterized by recurrent attacks of fever and serositis. Although colchicine prevents the …

[HTML][HTML] IL1-blocking therapy in colchicine-resistant familial Mediterranean fever

BM Köhler, HM Lorenz, N Blank - European journal of …, 2018 - ncbi.nlm.nih.gov
Objective Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show
an inadequate response to colchicine. In our cohort study, patients with FMF with or without …

IL-1β biological treatment of familial Mediterranean fever

A Soriano, E Verecchia, A Afeltra, R Landolfi… - Clinical Reviews in …, 2013 - Springer
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder
characterised by brief, recurring, self-limited episodes of fever and serositis resulting in …

[HTML][HTML] Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study

S Yoshida, Y Sumichika, K Saito, H Matsumoto… - Journal of Clinical …, 2023 - mdpi.com
Background: To investigate the clinical features of Japanese patients with Familial
Mediterranean Fever (FMF), we evaluated the frequency of attacks, treatment responses …

Evidence-based recommendations for the practical management of Familial Mediterranean Fever

V Hentgen, G Grateau, I Kone-Paut, A Livneh… - Seminars in arthritis and …, 2013 - Elsevier
Abstract Aim Familial Mediterranean Fever (FMF) is the most common recurrent
autoinflammatory fever syndrome. Still, many issues—eg: colchicine dosage adjustment …